Craft

Karyopharm Therapeutics

Stock Price

$0.8

2024-10-29

Market Capitalization

$111.7 M

2024-10-29

Revenue

$146 M

FY, 2023

Karyopharm Therapeutics Summary

Company Summary

Overview
Karyopharm Therapeutics is a commercial-stage pharmaceutical company that pioneers in cancer therapies. It focuses on XPO1 inhibition, myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL).
Type
Public
Status
Active
Founded
2008
HQ
Newton, MA, US | view all locations
Website
https://www.karyopharm.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Richard Paulson

    Richard Paulson, President, Chief Executive Officer and Director

  • Brian Austad

    Brian Austad, Senior Vice President, Pharmaceutical Sciences

  • Sharon Shacham

    Sharon Shacham, Founder and Scientific Advisory Board Member

  • James Accumanno

    James Accumanno, Chief Compliance Officer

Operating MetricsView all

Patents Issued

10

FY, 2015

LocationsView all

2 locations detected

  • Newton, MA HQ

    United States

    85 Wells Avenue, Suite 210

  • Givatayim, Tel Aviv District

    Israel

    4 Ariel Sharon Street

Karyopharm Therapeutics Financials

Summary Financials

Revenue (Q3, 2024)
$38.8M
Gross profit (Q3, 2024)
$37.5M
Net income (Q3, 2024)
($32.1M)
Cash (Q3, 2024)
$72.8M
EBIT (Q3, 2024)
($26.3M)
Enterprise value
$233.1M

Footer menu